

Stelara - (130mg/26mL ; Injection)

| | | | |
|------------------------------|---|-----------------------------|---------------------|
| Generic Name | Ustekinumab | Innovator | Janssen Pharma |
| Dosage | 130mg/26mL ; Injection | Branded US Sales | More Than \$1000 mn |
| Probable FTF | None | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | None | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | None |
| Indication | STELARA® is a human interleukin-12 and -23 antagonist indicated for the treatment of adult patients with : moderate to severe plaque psoriasis (Ps) who are candidates for phototherapy or systemic therapy; active psoriatic arthritis (PsA), alone or in combination with methotrexate; moderately to severely active Crohn's disease (CD) who have failed or were intolerant to treatment with immunomodulators or corticosteroids, but never failed a tumor necrosis factor (TNF) blocker, or failed or were intolerant to treatment with one or more TNF blockers. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.